CD8A and neoplasm: The data were confirmed in vivo in allograft murine breast cancer models: the treatment reduced tumor growth and metastases formation inhibited the release of TDEs expressing PD-L1, responsible for CD8+ T cell exhaustion, and reduced the number of immunosuppressive M2-type macrophages.